Valuation: AstraZeneca PLC

Market Cap 243B 210B 197B 179B 337B 23,239B 342B 2,308B 904B 11,643B 913B 893B 38,730B P/E 2026 *
20.1x
P/E 2027 * 17.5x
Enterprise Value 262B 227B 213B 194B 364B 25,087B 369B 2,491B 976B 12,569B 985B 964B 41,809B EV / Sales 2026 *
4.15x
EV / Sales 2027 * 3.81x
Free-Float
96.63%
Yield 2026 *
2.12%
Yield 2027 * 2.25%
1 day+0.61%
1 week-3.53%
Current month-8.51%
1 month-8.99%
3 months-12.75%
6 months-21.05%
Current year-12.59%
1 week 1,470.5
Extreme 1470.5
1,520
1 month 1,467
Extreme 1467
1,699
Current year 1,467
Extreme 1467
1,925.5
1 year 1,365
Extreme 1365
1,925.5
3 years 1,226
Extreme 1226
1,925.5
5 years 960.3
Extreme 960.3
1,925.5
10 years 461.3
Extreme 461.3
1,925.5
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+0.61%-3.53% - - 241B
+0.25%-3.96%+68.73%+120.06% 1,052B
+0.78%+0.21%+48.53%+50.78% 627B
+0.35%+0.95%+21.11%+66.86% 441B
+0.28%-4.56%+39.10%+38.05% 349B
+0.78%-2.68%+24.03%+37.32% 287B
+0.87%-3.59%-0.28%+7.12% 241B
+1.00%+0.52%+41.46%+58.95% 224B
-0.78%-4.49%-10.28%-54.13% 202B
+0.40%+4.40%+17.36%+81.59% 172B
Average +0.45%-1.20%+27.75%+45.18% 399.46B
Weighted average by Cap. +0.45%-1.70%+39.71%+63.88%

Financials

2026 *2027 *
Net sales 63.25B 54.6B 51.23B 46.66B 87.73B 6,048B 88.95B 601B 235B 3,030B 237B 232B 10,079B 66.85B 57.71B 54.14B 49.32B 92.73B 6,392B 94.01B 635B 249B 3,202B 251B 246B 10,652B
Net income 12.07B 10.42B 9.78B 8.9B 16.74B 1,154B 16.97B 115B 44.91B 578B 45.32B 44.33B 1,923B 13.72B 11.84B 11.11B 10.12B 19.02B 1,311B 19.29B 130B 51.03B 657B 51.49B 50.38B 2,185B
Net Debt 19.33B 16.68B 15.65B 14.26B 26.81B 1,848B 27.18B 183B 71.9B 926B 72.56B 70.99B 3,079B 11.66B 10.06B 9.44B 8.6B 16.17B 1,115B 16.4B 111B 43.38B 558B 43.77B 42.82B 1,858B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-08-17 SEK 1,489.00 +0.61% 833,287
26-08-14 SEK 1,480.00 -2.25% 687,282
26-08-13 SEK 1,514.00 +0.43% 303,617
26-08-12 SEK 1,507.50 -1.41% 545,575
26-08-11 SEK 1,529.00 -0.94% 659,012
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
156.71USD
Average target price
211.88USD
Spread / Average Target
+35.21%

Quarterly revenue - Rate of surprise